Form 4: Pfizer EVP Aamir Malik Granted 194,883 Stock Appreciation Rights

Pfizer's Executive Vice President, Aamir Malik, was granted 194,883 stock appreciation rights with an exercise price of $26.58, vesting on March 3, 2031.

Summary

• Aamir Malik, Executive Vice President of Pfizer Inc., was granted 194,883 Stock Appreciation Rights (SARs) on March 3, 2026.
• The SARs have an exercise price of $26.58.
• These SARs will be settled in shares of Pfizer common stock.
• The vesting and expiration date for these rights is March 3, 2031, which is the fifth anniversary of the grant date.
• The grant is subject to certain vesting requirements.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns executive incentives with long-term shareholder value, a standard and healthy practice for corporate governance.

Positives

• The grant of Stock Appreciation Rights aligns the executive's interests with long-term shareholder value creation.
• The five-year vesting schedule encourages executive retention and performance over a significant period.

Negatives

• No direct negatives are apparent from this grant disclosure.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

No forward-looking statements or guidance are provided beyond the vesting and settlement schedule of the Stock Appreciation Rights.

Industry Context

StockSavvy.ai notes that equity grants like Stock Appreciation Rights are a common component of executive compensation packages in the pharmaceutical industry, designed to incentivize long-term performance and align executive interests with shareholder returns. This is a standard practice for retaining key talent in competitive sectors.

Comparison to Industry Standards

• Equity grants, particularly performance-based awards like SARs, are a standard compensation tool across large-cap pharmaceutical companies such as Johnson & Johnson, Merck, and Bristol Myers Squibb.
• The structure of a five-year vesting period is typical for long-term incentive plans, aiming to foster sustained growth and executive retention.

Related Party Transactions

• This is an insider transaction involving Aamir Malik, an Executive Vice President of Pfizer Inc.

Stakeholder Impact

• Shareholders: The grant of SARs aligns the executive's financial interests with the company's stock performance, potentially benefiting shareholders through improved long-term value creation.
• Employees: No direct impact on general employees is indicated, but it reflects the company's executive compensation strategy.

Next Steps

• The Stock Appreciation Rights will be settled in shares of Pfizer common stock on March 3, 2031, subject to certain vesting requirements.

Key Dates

Recommendation

This Form 4 filing details a routine executive equity grant, which is a standard part of compensation and aligns executive interests with long-term company performance. It does not provide new information that would fundamentally alter the investment thesis for Pfizer, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Pfizer, PFE, Stock Appreciation Rights, SARs, Executive Compensation, Insider Transaction, Aamir Malik, Equity Grant, Form 4